Phase 3 trial in 152 adults with primary ITP after first-line steroids: ianalumab 9 or 3 mg/kg plus eltrombopag lengthened time to treatment failure vs placebo (HR 0.55 and 0.58). Serious adverse events: 16%, 6% and 4%.
RCTn = 152
Cuker et al. Ianalumab plus Eltrombopag in Immune Thrombocytopenia